Will PER follow DXB on a similar journey ?

Wow
Dxb still in phase 3
Trial results in 2025 ( 2nd interim results )
Im confident Per will secure a Big Pharma or two while we are in Phase 2b
because if the 6 month readout is successful
the Partner will carry on funding the next 6 months with the 45 boys
But
If the readout is spectacular Per will go to the FDA for accelerated approval and commercialisation ..Big Pharma will have to pay a great deal more..
DXB : FSGS market is >200,000 @US $120,000 per annum..
Note
Per has a much bigger market with multiple indications
$$
Not rubbishing DXB or PYC
just trying to get a handle what PER will be worth in Time
IMO: >$5